For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Angiodynamic Inc (NASDAQ: ANGO) closed at $9.11 in the last session, down -1.09% from day before closing price of $9.21. In other words, the price has decreased by -$1.09 from its previous closing price. On the day, 0.55 million shares were traded. ANGO stock price reached its highest trading level at $9.35 during the session, while it also had its lowest trading level at $9.07.
Ratios:
We take a closer look at ANGO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.40 and its Current Ratio is at 2.21. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Lake Street on July 16, 2025, initiated with a Buy rating and assigned the stock a target price of $24.
On April 05, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $12.
On September 25, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $19.H.C. Wainwright initiated its Buy rating on September 25, 2023, with a $19 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 16 ’25 when Nighan Warren JR sold 4,060 shares for $12.31 per share. The transaction valued at 49,979 led to the insider holds 41,817 shares of the business.
Nighan Warren JR bought 4,060 shares of ANGO for $49,979 on Jan 16 ’25. On Oct 07 ’24, another insider, Nighan Warren JR, who serves as the SVP Quality and Regulatory of the company, bought 768 shares for $6.09 each. As a result, the insider paid 4,677 and bolstered with 45,777 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ANGO now has a Market Capitalization of 370174816 and an Enterprise Value of 324427680. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.27 while its Price-to-Book (P/B) ratio in mrq is 2.04. Its current Enterprise Value per Revenue stands at 1.109 whereas that against EBITDA is -195.203.
Stock Price History:
The Beta on a monthly basis for ANGO is 0.67, which has changed by 0.19084966 over the last 52 weeks, in comparison to a change of 0.16564083 over the same period for the S&P500. Over the past 52 weeks, ANGO has reached a high of $13.50, while it has fallen to a 52-week low of $5.83. The 50-Day Moving Average of the stock is -7.13%, while the 200-Day Moving Average is calculated to be -1.11%.
Shares Statistics:
According to the various share statistics, ANGO traded on average about 637.87K shares per day over the past 3-months and 1232110 shares per day over the past 10 days. A total of 40.99M shares are outstanding, with a floating share count of 38.41M. Insiders hold about 5.47% of the company’s shares, while institutions hold 94.73% stake in the company. Shares short for ANGO as of 1751241600 were 2504981 with a Short Ratio of 3.93, compared to 1748563200 on 1932767. Therefore, it implies a Short% of Shares Outstanding of 2504981 and a Short% of Float of 7.510000499999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
At present, 3.0 analysts are actively evaluating the performance of Angiodynamic Inc (ANGO) in the stock market.The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.05 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.21 and -$0.33 for the fiscal current year, implying an average EPS of -$0.28. EPS for the following year is -$0.23, with 3.0 analysts recommending between -$0.2 and -$0.28.
Revenue Estimates
According to 3 analysts, the current quarter’s revenue is expected to be $74.26M. It ranges from a high estimate of $74.8M to a low estimate of $73.47M. As of the current estimate, Angiodynamic Inc’s year-ago sales were $70.98MFor the next quarter, 3 analysts are estimating revenue of $72.44M. There is a high estimate of $72.87M for the next quarter, whereas the lowest estimate is $72M.
A total of 3 analysts have provided revenue estimates for ANGO’s current fiscal year. The highest revenue estimate was $287.3M, while the lowest revenue estimate was $285.81M, resulting in an average revenue estimate of $286.65M. In the same quarter a year ago, actual revenue was $303.91MBased on 3 analysts’ estimates, the company’s revenue will be $304.86M in the next fiscal year. The high estimate is $308.9M and the low estimate is $302.5M.
